Treatment of allergic asthma: Modulation of Th2 cells and their responses

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Bosnjak, Berislav ^a   Stelzmueller, Barbara ^a   Erb, Klaus J ^b   Epstein, Michelle M ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b BoerhingerIngelheim Pharma   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR AFFECTING AGENT; ALLERGEN; ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHITOSAN; CIGLITAZONE; CORTICOSTEROID; CYTOKINE; CYTOKINE ANTIBODY; D PROSTANOID 1 RECEPTOR AGONIST; FINGOLIMOD; GAMMA SECRETASE INHIBITOR; IMMUNOMODULATING AGENT; KR 62890; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; MYCOLIC ACID; OX40 LIGAND ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROXYPHYLLINE; ROSIGLITAZONE; SO CHEONG RYONG TANG; SUPLATAST TOSYLATE; THYMIC STROMAL LYMPHOPOIETIN ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT;

ALLERGIC ASTHMA; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CELL ADHESION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSPNEA; EOSINOPHILIA; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE HOMING; REVIEW; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT OUTCOME; WHEEZING; ANIMAL; ASTHMA; GENE THERAPY; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CD4-POSITIVE T-LYMPHOCYTES; GENE THERAPY; HUMANS; HYPERSENSITIVITY; TH2 CELLS; TREATMENT OUTCOME;

EID: 80052028124     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-114     Document Type: Review

References (277)

1. Garlisi CG, Falcone A, Kung TT, Stelts D, Pennline KJ, Beavis AJ, Smith SR, Egan RW, Umland SP. T cells are necessary for Th2 cytokine production and eosinophil accumulation in airways of antigen-challenged allergic mice. Clin Immunol Immunopathol 1995, 75:75-83. 10.1006/clin.1995.1055, 7533686.
2. Leigh R, Ellis R, Wattie JN, Hirota JA, Matthaei KI, Foster PS, O'Byrne PM, Inman MD. Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice. Am J Respir Crit Care Med 2004, 169:860-867. 10.1164/rccm.200305-706OC, 14701709.
3. Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003, 111:450-463. 10.1067/mai.2003.169, 12642820.
4. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992, 326:298-304. 10.1056/NEJM199201303260504, 1530827.
5. Mojtabavi N, Dekan G, Stingl G, Epstein MM. Long-Lived Th2 Memory in Experimental Allergic Asthma. J Immunol 2002, 169:4788-4796.
6. Blackburn MR, Lee CG, Young HW, Zhu Z, Chunn JL, Kang MJ, Banerjee SK, Elias JA. Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. J Clin Invest 2003, 112:332-344. 166289, 12897202.
7. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science 1998, 282:2258-2261.
8. Zhu Z, Lee CG, Zheng T, Chupp G, Wang J, Homer RJ, Noble PW, Hamid Q, Elias JA. Airway inflammation and remodeling in asthma. Lessons from interleukin 11 and interleukin 13 transgenic mice. Am J Respir Crit Care Med 2001, 164:S67-70.
9. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008, 372:1073-1087. 10.1016/S0140-6736(08)61449-X, 18805336.
10. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31:143-178. 10.1183/09031936.00138707, 18166595.
11. Caramori G, Groneberg D, Ito K, Casolari P, Adcock IM, Papi A. New drugs targeting Th2 lymphocytes in asthma. J Occup Med Toxicol 2008, 3(Suppl 1):S6. 10.1186/1745-6673-3-S1-S6, 2259400, 18315837.
12. James LK, Durham SR. Update on mechanisms of allergen injection immunotherapy. Clin Exp Allergy 2008, 38:1074-1088. 10.1111/j.1365-2222.2008.02976.x, 18691292.
13. Esch RE. Sublingual immunotherapy. Curr Opin Otolaryngol Head Neck Surg 2008, 16:260-264. 10.1097/MOO.0b013e3282fc706f, 18475082.
14. Rolland JM, Gardner LM, O'Hehir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 2009, 121:273-284. 10.1016/j.pharmthera.2008.11.007, 19111571.
15. Reefer AJ, Carneiro RM, Custis NJ, Platts-Mills TA, Sung SS, Hammer J, Woodfolk JA. A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen. J Immunol 2004, 172:2763-2772.
16. Niederberger V. Allergen-specific immunotherapy. Immunol Lett 2009, 122:131-133. 10.1016/j.imlet.2008.11.012, 19100771.
17. Saltoun C, Avila PC. Advances in upper airway diseases and allergen immunotherapy in 2007. J Allergy Clin Immunol 2008, 122:481-487. 10.1016/j.jaci.2008.06.027, 18694591.
18. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007, 119:826-830. 10.1016/j.jaci.2007.01.025, 17335886.
19. Qiu J, Li GP, Liu ZG, Ran PX, Zhong NS. DNA vaccine encoding Der p2 allergen down-regulates STAT6 expression in mouse model of allergen-induced allergic airway inflammation. Chin Med J (Engl) 2006, 119:185-190.
20. Crameri R, Fluckiger S, Daigle I, Kundig T, Rhyner C. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007, 62:197-206.
21. Schabussova I, Wiedermann U. Lactic acid bacteria as novel adjuvant systems for prevention and treatment of atopic diseases. Curr Opin Allergy Clin Immunol 2008, 8:557-564. 10.1097/ACI.0b013e328317b88b, 18978472.
22. Larche M. Peptide immunotherapy for allergic diseases. Allergy 2007, 62:325-331. 10.1111/j.1398-9995.2006.01309.x, 17298351.
23. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008, 8:218-230. 10.1038/nri2262, 18274559.
24. Marazuela EG, Prado N, Moro E, Fernandez-Garcia H, Villalba M, Rodriguez R, Batanero E. Intranasal vaccination with poly(lactide-co-glycolide) microparticles containing a peptide T of Ole e 1 prevents mice against sensitization. Clin Exp Allergy 2008, 38:520-528. 10.1111/j.1365-2222.2007.02922.x, 18205856.
25. Medoff BD, Seung E, Hong S, Thomas SY, Sandall BP, Duffield JS, Kuperman DA, Erle DJ, Luster AD. CD11b+ myeloid cells are the key mediators of Th2 cell homing into the airway in allergic inflammation. J Immunol 2009, 182:623-635. 2718444, 19109196.
26. Rivas-Carvalho A, Meraz-Rios MA, Santos-Argumedo L, Bajana S, Soldevila G, Moreno-Garcia ME, Sanchez-Torres C. CD16+ human monocyte-derived dendritic cells matured with different and unrelated stimuli promote similar allogeneic Th2 responses: regulation by pro- and anti-inflammatory cytokines. Int Immunol 2004, 16:1251-1263. 10.1093/intimm/dxh127, 15277404.
27. Yerkovich ST, Roponen M, Smith ME, McKenna K, Bosco A, Subrata LS, Mamessier E, Wikstrom ME, Le Souef P, Sly PD, et al. Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141) expression on dendritic cells is associated with a TH2-skewed immune response. J Allergy Clin Immunol 2009, 123:209-216. e204, 10.1016/j.jaci.2008.09.009, 18947863.
28. Hammad H, de Vries VC, Maldonado-Lopez R, Moser M, Maliszewski C, Hoogsteden HC, Lambrecht BN. Differential capacity of CD8+ alpha or CD8- alpha dendritic cell subsets to prime for eosinophilic airway inflammation in the T-helper type 2-prone milieu of the lung. Clin Exp Allergy 2004, 34:1834-1840. 10.1111/j.1365-2222.2004.02133.x, 15663556.
29. Bertorelli G, Bocchino V, Zhou X, Zanini A, Bernini MV, Damia R, Di Comite V, Grima P, Olivieri D. Dendritic cell number is related to IL-4 expression in the airways of atopic asthmatic subjects. Allergy 2000, 55:449-454. 10.1034/j.1398-9995.2000.055005449.x, 10843425.
30. Moller GM, Overbeek SE, Van Helden-Meeuwsen CG, Van Haarst JM, Prens EP, Mulder PG, Postma DS, Hoogsteden HC. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulation by inhaled corticosteroids. Clin Exp Allergy 1996, 26:517-524. 10.1111/j.1365-2222.1996.tb00571.x, 8735863.
31. Bratke K, Lommatzsch M, Julius P, Kuepper M, Kleine HD, Luttmann W, Christian Virchow J. Dendritic cell subsets in human bronchoalveolar lavage fluid after segmental allergen challenge. Thorax 2007, 62:168-175. 10.1136/thx.2006.067793, 2111237, 16928719.
32. Chen XQ, Yang J, Hu SP, Nie HX, Mao GY, Chen HB. Increased expression of CD86 and reduced production of IL-12 and IL-10 by monocyte-derived dendritic cells from allergic asthmatics and their effects on Th1- and Th2-type cytokine balance. Respiration 2006, 73:34-40. 10.1159/000087457, 16106114.
33. Hammad H, Charbonnier AS, Duez C, Jacquet A, Stewart GA, Tonnel AB, Pestel J. Th2 polarization by Der p 1--pulsed monocyte-derived dendritic cells is due to the allergic status of the donors. Blood 2001, 98:1135-1141. 10.1182/blood.V98.4.1135, 11493462.
34. Long JA, Fogel-Petrovic M, Knight DA, Thompson PJ, Upham JW. Higher prostaglandin e2 production by dendritic cells from subjects with asthma compared with normal subjects. Am J Respir Crit Care Med 2004, 170:485-491. 10.1164/rccm.200311-1595OC, 15151923.
35. Hammad H, Lambrecht BN, Pochard P, Gosset P, Marquillies P, Tonnel AB, Pestel J. Monocyte-derived dendritic cells induce a house dust mite-specific Th2 allergic inflammation in the lung of humanized SCID mice: involvement of CCR7. J Immunol 2002, 169:1524-1534.
36. Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 1998, 161:2804-2809.
37. McIlroy A, Caron G, Blanchard S, Fremaux I, Duluc D, Delneste Y, Chevailler A, Jeannin P. Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells. Immunology 2006, 117:507-516. 10.1111/j.1365-2567.2006.02326.x, 1782249, 16556265.
38. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, Qin FX, Yao Z, Cao W, Liu YJ. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005, 202:1213-1223. 10.1084/jem.20051135, 2213234, 16275760.
39. Shi L, Leu SW, Xu F, Zhou X, Yin H, Cai L, Zhang L. Local blockade of TSLP receptor alleviated allergic disease by regulating airway dendritic cells. Clin Immunol 2008, 129:202-210. 10.1016/j.clim.2008.07.015, 18757241.
40. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008, 112:1557-1569. 10.1182/blood-2008-05-078154, 2518872, 18725574.
41. Zhang DH, Cohn L, Ray P, Bottomly K, Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem 1997, 272:21597-21603. 10.1074/jbc.272.34.21597, 9261181.
42. Yamashita M, Ukai-Tadenuma M, Miyamoto T, Sugaya K, Hosokawa H, Hasegawa A, Kimura M, Taniguchi M, DeGregori J, Nakayama T. Essential role of GATA3 for the maintenance of type 2 helper T (Th2) cytokine production and chromatin remodeling at the Th2 cytokine gene loci. J Biol Chem 2004, 279:26983-26990. 10.1074/jbc.M403688200, 15087456.
43. Pai SY, Truitt ML, Ho IC. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. Proc Natl Acad Sci USA 2004, 101:1993-1998. 10.1073/pnas.0308697100, 357040, 14769923.
44. Bi Y, Liu G, Yang R. MicroRNAs: novel regulators during the immune response. J Cell Physiol 2009, 218:467-472. 10.1002/jcp.21639, 19034913.
45. Lodish HF, Zhou B, Liu G, Chen CZ. Micromanagement of the immune system by microRNAs. Nat Rev Immunol 2008, 8:120-130. 10.1038/nri2252, 18204468.
46. Garbacki N, Di Valentin E, Huynh-Thu VA, Geurts P, Irrthum A, Crahay C, Arnould T, Deroanne C, Piette J, Cataldo D, Colige A. MicroRNAs profiling in murine models of acute and chronic asthma: a relationship with mRNAs targets. PLoS One 2011, 6:e16509. 10.1371/journal.pone.0016509, 3030602, 21305051.
47. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci 2009, 14:540-551.
48. Annunziato F, Cosmi L, Galli G, Beltrame C, Romagnani P, Manetti R, Romagnani S, Maggi E. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol 1999, 65:691-699.
49. Heijink IH, Van Oosterhout AJ. Strategies for targeting T-cells in allergic diseases and asthma. Pharmacol Ther 2006, 112:489-500. 10.1016/j.pharmthera.2006.05.005, 16814862.
50. Kuhn CF, Bazin M, Philippe L, Zhang J, Tylaska L, Miret J, Bauer PH. Bipiperidinyl carboxylic acid amides as potent, selective, and functionally active CCR4 antagonists. Chem Biol Drug Des 2007, 70:268-272. 10.1111/j.1747-0285.2007.00551.x, 17718722.
51. Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, Hall D, Bessant C, Bartholomew M, Howarth PH, et al. Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. J Immunol 2010, 184:4568-4574. 10.4049/jimmunol.0901342, 20237293.
52. Woodfolk JA. T-cell responses to allergens. J Allergy Clin Immunol 2007, 119:280-294. quiz 295-286, 10.1016/j.jaci.2006.11.008, 17291848.
53. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C, Buonsanti C, Miotto D, Mapp C, Villa A, et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest 2001, 107:1357-1364. 10.1172/JCI12655, 209325, 11390417.
54. Chung CD, Kuo F, Kumer J, Motani AS, Lawrence CE, Henderson WR, Venkataraman C. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J Immunol 2003, 170:581-587.
55. Mikhak Z, Fukui M, Farsidjani A, Medoff BD, Tager AM, Luster AD. Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation. J Allergy Clin Immunol 2009, 123:67-73. e63, 10.1016/j.jaci.2008.09.049, 2782398, 19062085.
56. Fox JM, Najarro P, Smith GL, Struyf S, Proost P, Pease JE. Structure/function relationships of CCR8 agonists and antagonists. Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist. J Biol Chem 2006, 281:36652-36661. 10.1074/jbc.M605584200, 17023422.
57. Jin J, Wang Y, Wang F, Kerns JK, Vinader VM, Hancock AP, Lindon MJ, Stevenson GI, Morrow DM, Rao P, et al. Oxazolidinones as novel human CCR8 antagonists. Bioorg Med Chem Lett 2007, 17:1722-1725. 10.1016/j.bmcl.2006.12.076, 17267215.
58. Gonzalo JA, Lloyd CM, Peled A, Delaney T, Coyle AJ, Gutierrez-Ramos JC. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. J Immunol 2000, 165:499-508.
59. Hu JS, Freeman CM, Stolberg VR, Chiu BC, Bridger GJ, Fricker SP, Lukacs NW, Chensue SW. AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation. Am J Pathol 2006, 169:424-432. 10.2353/ajpath.2006.051234, 1599788, 16877345.
60. Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002, 160:1353-1360. 10.1016/S0002-9440(10)62562-X, 1867206, 11943720.
61. Humbles AA, Lu B, Friend DS, Okinaga S, Lora J, Al-Garawi A, Martin TR, Gerard NP, Gerard C. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002, 99:1479-1484. 10.1073/pnas.261462598, 122216, 11830666.
62. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997, 277:2005-2007. 10.1126/science.277.5334.2005, 9302298.
63. Mori A, Ogawa K, Someya K, Kunori Y, Nagakubo D, Yoshie O, Kitamura F, Hiroi T, Kaminuma O. Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists. Int Immunol 2007, 19:913-921. 10.1093/intimm/dxm049, 17804691.
64. Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong M, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008, 177:952-958. 10.1164/rccm.200708-1251OC, 18244953.
65. Kallinich T, Schmidt S, Hamelmann E, Fischer A, Qin S, Luttmann W, Virchow JC, Kroczek RA. Chemokine-receptor expression on T cells in lung compartments of challenged asthmatic patients. Clin Exp Allergy 2005, 35:26-33. 10.1111/j.1365-2222.2004.02132.x, 15649262.
66. Thomas SY, Banerji A, Medoff BD, Lilly CM, Luster AD. Multiple chemokine receptors, including CCR6 and CXCR3, regulate antigen-induced T cell homing to the human asthmatic airway. J Immunol 2007, 179:1901-1912.
67. Mionnet C, Buatois V, Kanda A, Milcent V, Fleury S, Lair D, Langelot M, Lacoeuille Y, Hessel E, Coffman R, et al. CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung. Nat Med 2010, 16:1305-1312. 10.1038/nm.2253, 21037587.
68. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849-1861. 10.1084/jem.20070663, 2118657, 17635957.
69. Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol 2008, 153(Suppl 1):S191-199. 2268053, 17965752.
70. Royer JF, Schratl P, Carrillo JJ, Jupp R, Barker J, Weyman-Jones C, Beri R, Sargent C, Schmidt JA, Lang-Loidolt D, Heinemann A. A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils. Eur J Clin Invest 2008, 38:663-671. 10.1111/j.1365-2362.2008.01989.x, 18837743.
71. Lukacs NW, Berlin AA, Franz-Bacon K, Sasik R, Sprague LJ, Ly TW, Hardiman G, Boehme SA, Bacon KB. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. Am J Physiol Lung Cell Mol Physiol 2008, 295:L767-779. 10.1152/ajplung.90351.2008, 2584886, 18757520.
72. Stebbins KJ, Broadhead AR, Correa LD, Scott JM, Truong YP, Stearns BA, Hutchinson JH, Prasit P, Evans JF, Lorrain DS. Therapeutic efficacy of AM156, a novel prostanoid DP2 receptor antagonist, in murine models of allergic rhinitis and house dust mite-induced pulmonary inflammation. Eur J Pharmacol 2010, 638:142-149. 10.1016/j.ejphar.2010.04.031, 20447387.
73. Torres D, Paget C, Fontaine J, Mallevaey T, Matsuoka T, Maruyama T, Narumiya S, Capron M, Gosset P, Faveeuw C, Trottein F. Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. J Immunol 2008, 180:783-792.
74. Schuligoi R, Sedej M, Waldhoer M, Vukoja A, Sturm EM, Lippe IT, Peskar BA, Heinemann A. Prostaglandin H2 induces the migration of human eosinophils through the chemoattractant receptor homologous molecule of Th2 cells, CRTH2. J Leukoc Biol 2009, 85:136-145.
75. Tajima T, Murata T, Aritake K, Urade Y, Hirai H, Nakamura M, Ozaki H, Hori M. Lipopolysaccharide induces macrophage migration via prostaglandin D(2) and prostaglandin E(2). J Pharmacol Exp Ther 2008, 326:493-501. 10.1124/jpet.108.137992, 18492946.
76. Porter JC, Hall A. Epithelial ICAM-1 and ICAM-2 regulate the egression of human T cells across the bronchial epithelium. Faseb J 2009, 23:492-502. 2630786, 18842965.
77. Furusho S, Myou S, Fujimura M, Kita T, Yasui M, Kasahara K, Nakao S, Takehara K, Sato S. Role of intercellular adhesion molecule-1 in a murine model of toluene diisocyanate-induced asthma. Clin Exp Allergy 2006, 36:1294-1302. 10.1111/j.1365-2222.2006.02568.x, 17014439.
78. Ueki S, Kihara J, Kato H, Ito W, Takeda M, Kobayashi Y, Kayaba H, Chihara J. Soluble vascular cell adhesion molecule-1 induces human eosinophil migration. Allergy 2009, 64:718-724. 10.1111/j.1398-9995.2008.01871.x, 19210349.
79. Parmley LA, Elkins ND, Fini MA, Liu YE, Repine JE, Wright RM. Alpha-4/beta-1 and alpha-L/beta-2 integrins mediate cytokine induced lung leukocyte-epithelial adhesion and injury. Br J Pharmacol 2007, 152:915-929. 10.1038/sj.bjp.0707443, 2078224, 17828290.
80. Kelly M, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007, 120:3-10. 10.1016/j.jaci.2007.05.017, 17559914.
81. Mackay CR. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 2008, 9:988-998. 10.1038/ni.f.210, 18711436.
82. Kenyon NJ, Liu R, O'Roark EM, Huang W, Peng L, Lam KS. An alpha4 beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. Eur J Pharmacol 2009, 603:138-146. 10.1016/j.ejphar.2008.11.063, 2646171, 19103195.
83. Ravensberg AJ, Luijk B, Westers P, Hiemstra PS, Sterk PJ, Lammers JW, Rabe KF. The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma. Allergy 2006, 61:1097-1103. 10.1111/j.1398-9995.2006.01146.x, 16918513.
84. Davenport RJ, Munday JR. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?. Drug Discov Today 2007, 12:569-576. 10.1016/j.drudis.2007.05.001, 17631252.
85. Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N. A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid. Bioorg Med Chem 2009, 17:1232-1243. 10.1016/j.bmc.2008.12.026, 19124247.
86. Saku O, Ohta K, Arai E, Nomoto Y, Miura H, Nakamura H, Fuse E, Nakasato Y. Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives. Bioorg Med Chem Lett 2008, 18:1053-1057. 10.1016/j.bmcl.2007.12.014, 18160288.
87. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 2009, 102:823-828.
88. Duong M, Cockcroft D, Boulet LP, Ahmed T, Iverson H, Atkinson DC, Stahl EG, Watson R, Davis B, Milot J, et al. The effect of IVX-0142, a heparin-derived hypersulfated disaccharide, on the allergic airway responses in asthma. Allergy 2008, 63:1195-1201. 10.1111/j.1398-9995.2008.01707.x, 18699936.
89. Spinozzi F, de Benedictis D, de Benedictis FM. Apoptosis, airway inflammation and anti-asthma therapy: from immunobiology to clinical application. Pediatr Allergy Immunol 2008, 19:287-295. 10.1111/j.1399-3038.2007.00668.x, 18179617.
90. Simon HU. Cell death in allergic diseases. Apoptosis 2009, 14:439-446. 10.1007/s10495-008-0299-1, 19130232.
91. Ohkusu-Tsukada K, Tsukada T, Isobe K. Accelerated development and aging of the immune system in p53-deficient mice. J Immunol 1999, 163:1966-1972.
92. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA. Molecular basis of T cell inactivation by CTLA-4. Science 1998, 282:2263-2266.
93. da Rocha Dias S, Rudd CE. CTLA-4 blockade of antigen-induced cell death. Blood 2001, 97:1134-1137. 10.1182/blood.V97.4.1134, 11159548.
94. Ubaldi V, Gatta L, Pace L, Doria G, Pioli C. CTLA-4 engagement inhibits Th2 but not Th1 cell polarisation. Clin Dev Immunol 2003, 10:13-17. 10.1080/10446670310001598519, 2270672, 14575153.
95. Abdulamir AS, Hafidh RR, Abubakar F, Abbas KA. Changing survival, memory cell compartment, and T-helper balance of lymphocytes between severe and mild asthma. BMC Immunol 2008, 9:73. 10.1186/1471-2172-9-73, 2631545, 19087256.
96. Ramsdell F, Seaman MS, Miller RE, Picha KS, Kennedy MK, Lynch DH. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol 1994, 6:1545-1553. 10.1093/intimm/6.10.1545, 7530039.
97. Fang Y, Yu S, Ellis JS, Sharav T, Braley-Mullen H. Comparison of sensitivity of Th1, Th2, and Th17 cells to Fas-mediated apoptosis. J Leukoc Biol 2010, 87:1019-1028. 10.1189/jlb.0509352, 2872534, 20179154.
98. Tong J, Clay BS, Ferreira CM, Bandukwala HS, Moore TV, Blaine KM, Williams JW, Hoffman LM, Hamann KJ, Shilling RA, et al. Fas ligand expression on T Cells is sufficient to prevent prolonged airway inflammation in a murine model of asthma. Am J Respir Cell Mol Biol 2010, 43:342-348. 10.1165/rcmb.2008-0454OC, 2933550, 19855087.
99. Wang Y, Bi Y, Wu K, Wang C. Dendritic cell co-transfected with FasL and allergen genes induces T cell tolerance and decreases airway inflammation in allergen induced murine model. Mol Biol Rep 2011, 38:809-817. 10.1007/s11033-010-0170-7, 20373028.
100. Devadas S, Das J, Liu C, Zhang L, Roberts AI, Pan Z, Moore PA, Das G, Shi Y. Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity 2006, 25:237-247. 10.1016/j.immuni.2006.06.011, 16901729.
101. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006, 61:729-734. 10.1136/thx.2005.057976, 2104700, 16877692.
102. Robinson AJ, Kashanin D, O'Dowd F, Fitzgerald K, Williams V, Walsh GM. Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions. Clin Exp Allergy 2009, 39:1866-1874. 10.1111/j.1365-2222.2009.03334.x, 19689459.
103. Kim DY, Ryu SY, Lim JE, Lee YS, Ro JY. Anti-inflammatory mechanism of simvastatin in mouse allergic asthma model. Eur J Pharmacol 2007, 557:76-86. 10.1016/j.ejphar.2006.11.027, 17169357.
104. Imamura M, Okunishi K, Ohtsu H, Nakagome K, Harada H, Tanaka R, Yamamoto K, Dohi M. Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax 2009, 64:44-49.
105. Chiba Y, Arima J, Sakai H, Misawa M. Lovastatin inhibits bronchial hyperresponsiveness by reducing RhoA signaling in rat allergic asthma. Am J Physiol Lung Cell Mol Physiol 2008, 294:L705-713. 10.1152/ajplung.00531.2007, 18296496.
106. Zhou Q, Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des 2009, 15:3108-3115. 10.2174/138161209789057986, 2896789, 19754385.
107. Schaafsma D, Gosens R, Zaagsma J, Halayko AJ, Meurs H. Rho kinase inhibitors: a novel therapeutical intervention in asthma?. Eur J Pharmacol 2008, 585:398-406. 10.1016/j.ejphar.2008.01.056, 18410919.
108. Aihara M, Dobashi K, Iizuka K, Nakazawa T, Mori M. Effect of Y-27632 on release of cytokines from peripheral T cells in asthmatic patients and normal subjects. Int Immunopharmacol 2004, 4:557-561. 10.1016/j.intimp.2003.12.014, 15099533.
109. Lin J, Kane LP. Are TIM proteins involved in asthma development or pathology?. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology 2011, 41:917-919.
110. Su EW, Lin JY, Kane LP. TIM-1 and TIM-3 proteins in immune regulation. Cytokine 2008, 44:9-13. 10.1016/j.cyto.2008.06.013, 2574986, 18706830.
111. Kuchroo VK, Dardalhon V, Xiao S, Anderson AC. New roles for TIM family members in immune regulation. Nat Rev Immunol 2008, 8:577-580. 10.1038/nri2366, 18617884.
112. Grigorian A, Torossian S, Demetriou M. T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol Rev 2009, 230:232-246. 10.1111/j.1600-065X.2009.00796.x, 3059806, 19594640.
113. Ge XN, Bahaie NS, Kang BN, Hosseinkhani MR, Ha SG, Frenzel EM, Liu FT, Rao SP, Sriramarao P. Allergen-induced airway remodeling is impaired in galectin-3-deficient mice. J Immunol 2010, 185:1205-1214. 10.4049/jimmunol.1000039, 2918241, 20543100.
114. Lopez E, del Pozo V, Miguel T, Sastre B, Seoane C, Civantos E, Llanes E, Baeza ML, Palomino P, Cardaba B, et al. Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. J Immunol 2006, 176:1943-1950.
115. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R, Niki T, Nishi N, Tominaga A, Yamauchi A, Hirashima M. Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med 2007, 176:27-35. 10.1164/rccm.200608-1243OC, 17446336.
116. Varki A, Angata T. Siglecs--the major subfamily of I-type lectins. Glycobiology 2006, 16:1R-27R. 10.1093/glycob/cwj126, 16014749.
117. Angata T, Margulies EH, Green ED, Varki A. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:13251-13256. 10.1073/pnas.0404833101, 516556, 15331780.
118. Zhang M, Angata T, Cho JY, Miller M, Broide DH, Varki A. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 2007, 109:4280-4287. 10.1182/blood-2006-08-039255, 1885492, 17272508.
119. Song DJ, Cho JY, Lee SY, Miller M, Rosenthal P, Soroosh P, Croft M, Zhang M, Varki A, Broide DH. Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling. Journal of immunology 2009, 183:5333-5341.
120. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. Loss of Siglec expression on T lymphocytes during human evolution. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:7765-7770. 10.1073/pnas.0510484103, 1472519, 16682635.
121. King NE, Rothenberg ME, Zimmermann N. Arginine in asthma and lung inflammation. J Nutr 2004, 134:2830S-2836S. discussion 2853S.
122. Maarsingh H, Zaagsma J, Meurs H. Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br J Pharmacol 2009, 158:652-664. 10.1111/j.1476-5381.2009.00374.x, 2765587, 19703164.
123. Zimmermann N, King NE, Laporte J, Yang M, Mishra A, Pope SM, Muntel EE, Witte DP, Pegg AA, Foster PS, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003, 111:1863-1874. 161427, 12813022.
124. Yang M, Rangasamy D, Matthaei KI, Frew AJ, Zimmmermann N, Mahalingam S, Webb DC, Tremethick DJ, Thompson PJ, Hogan SP, et al. Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J Immunol 2006, 177:5595-5603.
125. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM, Thompson RW, Cheever AW, Murray PJ, Wynn TA. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 2009, 5:e1000371. 10.1371/journal.ppat.1000371, 2660425, 19360123.
126. Su RC, Becker AB, Kozyrskyj AL, Hayglass KT. Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J Allergy Clin Immunol 2008, 121:57-63. e53, 10.1016/j.jaci.2007.09.004, 17980413.
127. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005, 35:89-96. 10.1111/j.1365-2222.2004.02006.x, 15649272.
128. Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R, Zhang Y, Rembold M, Gaisberger M, Hartl A, et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol 2010, 185:3489-3497. 10.4049/jimmunol.0903610, 3175530, 20702731.
129. Debarry J, Garn H, Hanuszkiewicz A, Dickgreber N, Blumer N, von Mutius E, Bufe A, Gatermann S, Renz H, Holst O, Heine H. Acinetobacter lwoffii and Lactococcus lactis strains isolated from farm cowsheds possess strong allergy-protective properties. J Allergy Clin Immunol 2007, 119:1514-1521. 10.1016/j.jaci.2007.03.023, 17481709.
130. Smit JJ, Folkerts G, Nijkamp FP. Mycobacteria, genes and the 'hygiene hypothesis'. Curr Opin Allergy Clin Immunol 2004, 4:57-62. 10.1097/00130832-200402000-00012, 15090921.
131. Christ AP, Rodriguez D, Bortolatto J, Borducchi E, Keller A, Mucida D, Silva JS, Leite LC, Russo M. Enhancement of Th1 Lung Immunity Induced by Recombinant Mycobacterium bovis BCG Attenuates Airway Allergic Disease. Am J Respir Cell Mol Biol 2009,
132. Yokoi T, Amakawa R, Tanijiri T, Sugimoto H, Torii Y, Amuro H, Son Y, Tajima K, Liu YJ, Ito T, Fukuhara S. Mycobacterium bovis Bacillus Calmette-Guerin suppresses inflammatory Th2 responses by inducing functional alteration of TSLP-activated dendritic cells. Int Immunol 2008, 20:1321-1329. 10.1093/intimm/dxn094, 18703465.
133. Ou-Yang HF, Hu XB, Ti XY, Shi JR, Li SJ, Qi HW, Wu CG. Suppression of allergic airway inflammation in a mouse model by Der p2 recombined BCG. Immunology 2009, 128:e343-352. 10.1111/j.1365-2567.2008.02970.x, 2753957, 19191902.
134. Wu Q, Martin RJ, Lafasto S, Chu HW. A low dose of Mycoplasma pneumoniae infection enhances an established allergic inflammation in mice: the role of the prostaglandin E2 pathway. Clin Exp Allergy 2009, 39:1754-1763. 10.1111/j.1365-2222.2009.03309.x, 2784117, 19552640.
135. Delayre-Orthez C, de Blay F, Frossard N, Pons F. Dose-dependent effects of endotoxins on allergen sensitization and challenge in the mouse. Clin Exp Allergy 2004, 34:1789-1795. 10.1111/j.1365-2222.2004.02082.x, 15544606.
136. Ichikawa S, Takai T, Yashiki T, Takahashi S, Okumura K, Ogawa H, Kohda D, Hatanaka H. Lipopolysaccharide binding of the mite allergen Der f 2. Genes Cells 2009, 14:1055-1065. 10.1111/j.1365-2443.2009.01334.x, 19678854.
137. Inohara N, Nunez G. ML -- a conserved domain involved in innate immunity and lipid metabolism. Trends Biochem Sci 2002, 27:219-221. 10.1016/S0968-0004(02)02084-4, 12076526.
138. Klinman D, Shirota H, Tross D, Sato T, Klaschik S. Synthetic oligonucleotides as modulators of inflammation. J Leukoc Biol 2008, 84:958-964. 10.1189/jlb.1107775, 2538593, 18430787.
139. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev 2009, 61:256-262. 10.1016/j.addr.2008.12.007, 19167442.
140. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999, 162:6284-6293.
141. Constabel H, Stankov MV, Hartwig C, Tschernig T, Behrens GM. Impaired lung dendritic cell migration and T cell stimulation induced by immunostimulatory oligonucleotides contribute to reduced allergic airway inflammation. J Immunol 2009, 183:3443-3453. 10.4049/jimmunol.0804223, 19667097.
142. Hessel EM, Chu M, Lizcano JO, Chang B, Herman N, Kell SA, Wills-Karp M, Coffman RL. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med 2005, 202:1563-1573. 10.1084/jem.20050631, 2213327, 16314434.
143. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Muller P, Pfister T, Maurer P, Bachmann MF, Graf N, Kundig TM. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009, 39:562-570. 10.1111/j.1365-2222.2008.03191.x, 19226280.
144. Angeli V, Hammad H, Staels B, Capron M, Lambrecht BN, Trottein F. Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response. J Immunol 2003, 170:5295-5301.
145. Hammad H, de Heer HJ, Soullie T, Angeli V, Trottein F, Hoogsteden HC, Lambrecht BN. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am J Pathol 2004, 164:263-271. 10.1016/S0002-9440(10)63116-1, 1602239, 14695339.
146. Hutchison S, Choo-Kang BS, Gibson VB, Bundick RV, Leishman AJ, Brewer JM, McInnes IB, Garside P. An investigation of the impact of the location and timing of antigen-specific T cell division on airways inflammation. Clin Exp Immunol 2009, 155:107-116. 10.1111/j.1365-2249.2008.03800.x, 2665686, 19076834.
147. Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, Soullie T, Willart MA, Hijdra D, Hoogsteden HC, Lambrecht BN. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006, 116:2935-2944. 10.1172/JCI28295, 1626118, 17080194.
148. Nishiuma T, Nishimura Y, Okada T, Kuramoto E, Kotani Y, Jahangeer S, Nakamura S. Inhalation of sphingosine kinase inhibitor attenuates airway inflammation in asthmatic mouse model. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1085-1093. 10.1152/ajplung.00445.2007, 18359884.
149. Sawicka E, Zuany-Amorim C, Manlius C, Trifilieff A, Brinkmann V, Kemeny DM, Walker C. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol 2003, 171:6206-6214.
150. Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin Ther Pat 2009, 19:295-303. 10.1517/13543770902755129, 19441905.
151. Pichavant M, Charbonnier AS, Taront S, Brichet A, Wallaert B, Pestel J, Tonnel AB, Gosset P. Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment. J Allergy Clin Immunol 2005, 115:771-778. 10.1016/j.jaci.2004.11.043, 15805997.
152. Ip WK, Wong CK, Lam CW. Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathways. Clin Exp Immunol 2006, 145:162-172. 10.1111/j.1365-2249.2006.03085.x, 1942012, 16792687.
153. Hammad H, Kool M, Soullie T, Narumiya S, Trottein F, Hoogsteden HC, Lambrecht BN. Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells. J Exp Med 2007, 204:357-367. 10.1084/jem.20061196, 2118726, 17283205.
154. Crosby JR, Guha M, Tung D, Miller DA, Bender B, Condon TP, York-DeFalco C, Geary RS, Monia BP, Karras JG, Gregory SA. Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther 2007, 321:938-946. 10.1124/jpet.106.119214, 17389243.
155. Yokomura K, Suda T, Matsuda H, Hashizume H, Asada K, Suzuki K, Chida K. Suplatast tosilate alters DC1/DC2 balance in peripheral blood in bronchial asthma. J Asthma 2005, 42:567-570. 10.1080/02770900500215913, 16169790.
156. Chen YQ, Shi HZ. CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma. Allergy 2006, 61:15-26.
157. Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, Zhang J, Diehl L, Austin CD, Meng YG, Tan M, et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest 2007, 117:3868-3878. 10.1172/JCI33559, 2096422, 18060034.
158. Singh AK, Stock P, Akbari O. Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy 2011, 66:155-162. 10.1111/j.1398-9995.2010.02458.x, 20722638.
159. Tilley SL, Boucher RC. A1 antagonism in asthma: better than coffee?. J Clin Invest 2005, 115:13-16. 539211, 15630434.
160. Lopez-Castejon G, Baroja-Mazo A, Pelegrin P. Novel macrophage polarization model: from gene expression to identification of new anti-inflammatory molecules. Cell Mol Life Sci 2010,
161. Chen CL, Wang YM, Liu CF, Wang JY. The effect of water-soluble chitosan on macrophage activation and the attenuation of mite allergen-induced airway inflammation. Biomaterials 2008, 29:2173-2182. 10.1016/j.biomaterials.2008.01.023, 18279951.
162. Korf JE, Pynaert G, Tournoy K, Boonefaes T, Van Oosterhout A, Ginneberge D, Haegeman A, Verschoor JA, De Baetselier P, Grooten J. Macrophage reprogramming by mycolic acid promotes a tolerogenic response in experimental asthma. Am J Respir Crit Care Med 2006, 174:152-160. 10.1164/rccm.200507-1175OC, 16675779.
163. Perrigoue JG, Saenz SA, Siracusa MC, Allenspach EJ, Taylor BC, Giacomin PR, Nair MG, Du Y, Zaph C, van Rooijen N, et al. MHC class II-dependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol 2009, 10:697-705. 10.1038/ni.1740, 2711559, 19465906.
164. Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 2008, 9:310-318. 10.1038/ni1558, 18300366.
165. Sokol CL, Chu NQ, Yu S, Nish SA, Laufer TM, Medzhitov R. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol 2009, 10:713-720. 10.1038/ni.1738, 19465907.
166. Yoshimoto T, Yasuda K, Tanaka H, Nakahira M, Imai Y, Fujimori Y, Nakanishi K. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 2009, 10:706-712. 10.1038/ni.1737, 19465908.
167. Hammad H, Plantinga M, Deswarte K, Pouliot P, Willart MA, Kool M, Muskens F, Lambrecht BN. Inflammatory dendritic cells--not basophils--are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. J Exp Med 2010, 207:2097-2111. 10.1084/jem.20101563, 2947072, 20819925.
168. Kim S, Prout M, Ramshaw H, Lopez AF, LeGros G, Min B. Cutting edge: basophils are transiently recruited into the draining lymph nodes during helminth infection via IL-3, but infection-induced Th2 immunity can develop without basophil lymph node recruitment or IL-3. Journal of immunology 2010, 184:1143-1147.
169. Ho IC, Tai TS, Pai SY. GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation. Nat Rev Immunol 2009, 9:125-135. 10.1038/nri2476, 2998182, 19151747.
170. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001, 193:1247-1260. 10.1084/jem.193.11.1247, 2193377, 11390432.
171. Lee CC, Huang HY, Chiang BL. Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol Ther 2008, 16:60-65. 10.1038/sj.mt.6300309, 17878900.
172. Stritesky GL, Muthukrishnan R, Sehra S, Goswami R, Pham D, Travers J, Nguyen ET, Levy DE, Kaplan MH. The transcription factor STAT3 is required for T helper 2 cell development. Immunity 2011, 34:39-49. 10.1016/j.immuni.2010.12.013, 21215659.
173. Simeone-Penney MC, Severgnini M, Tu P, Homer RJ, Mariani TJ, Cohn L, Simon AR. Airway epithelial STAT3 is required for allergic inflammation in a murine model of asthma. J Immunol 2007, 178:6191-6199.
174. Kagami S, Nakajima H, Kumano K, Suzuki K, Suto A, Imada K, Davey HW, Saito Y, Takatsu K, Leonard WJ, Iwamoto I. Both stat5a and stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue. Blood 2000, 95:1370-1377.
175. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005, 6:1152-1159. 10.1038/ni1264, 16227983.
176. Ohga K, Kuromitsu S, Takezawa R, Numazaki M, Ishikawa J, Nagashima S, Shimizu Y. YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models. Eur J Pharmacol 2008, 590:409-416. 10.1016/j.ejphar.2008.06.035, 18590722.
177. Walker W, Healey GD, Hopkin JM. RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology 2009, 127:256-266. 10.1111/j.1365-2567.2008.02951.x, 2691791, 19175798.
178. Amsen D, Antov A, Jankovic D, Sher A, Radtke F, Souabni A, Busslinger M, McCright B, Gridley T, Flavell RA. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 2007, 27:89-99. 10.1016/j.immuni.2007.05.021, 2062505, 17658279.
179. Fang TC, Yashiro-Ohtani Y, Del Bianco C, Knoblock DM, Blacklow SC, Pear WS. Notch directly regulates Gata3 expression during T helper 2 cell differentiation. Immunity 2007, 27:100-110. 10.1016/j.immuni.2007.04.018, 2801546, 17658278.
180. Kang JH, Kim BS, Uhm TG, Lee SH, Lee GR, Park CS, Chung IY. Gamma-secretase inhibitor reduces allergic pulmonary inflammation by modulating Th1 and Th2 responses. Am J Respir Crit Care Med 2009, 179:875-882. 10.1164/rccm.200806-893OC, 19234107.
181. Tu L, Fang TC, Artis D, Shestova O, Pross SE, Maillard I, Pear WS. Notch signaling is an important regulator of type 2 immunity. J Exp Med 2005, 202:1037-1042. 10.1084/jem.20050923, 2213210, 16230473.
182. Kovall RA. More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene 2008, 27:5099-5109. 10.1038/onc.2008.223, 18758478.
183. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009, 16:633-647. 10.1016/j.devcel.2009.03.010, 19460341.
184. Ho IC, Hodge MR, Rooney JW, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996, 85:973-983. 10.1016/S0092-8674(00)81299-4, 8674125.
185. Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med 1998, 188:1859-1866. 10.1084/jem.188.10.1859, 2212398, 9815263.
186. Ko E, Rho S, Cho C, Choi H, Ko S, Lee Y, Hong MC, Shin MK, Jung SG, Bae H. So-Cheong-Ryong-Tang, tradititional Korean medicine, suppresses Th2 lineage development. Biol Pharm Bull 2004, 27:739-743. 10.1248/bpb.27.739, 15133258.
187. Won HY, Min HJ, Ahn JH, Yoo SE, Bae MA, Hong JH, Hwang ES. Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation. Biochem Pharmacol 2009,
188. Liu Z, Li Z, Mao K, Zou J, Wang Y, Tao Z, Lin G, Tian L, Ji Y, Wu X, et al. Dec2 promotes Th2 cell differentiation by enhancing IL-2R signaling. J Immunol 2009, 183:6320-6329. 10.4049/jimmunol.0900975, 19880450.
189. Yang XO, Angkasekwinai P, Zhu J, Peng J, Liu Z, Nurieva R, Liu X, Chung Y, Chang SH, Sun B, Dong C. Requirement for the basic helix-loop-helix transcription factor Dec2 in initial TH2 lineage commitment. Nat Immunol 2009, 10:1260-1266. 10.1038/ni.1821, 2784129, 19881507.
190. Shinnakasu R, Yamashita M, Kuwahara M, Hosokawa H, Hasegawa A, Motohashi S, Nakayama T. Gfi1-mediated stabilization of GATA3 protein is required for Th2 cell differentiation. J Biol Chem 2008, 283:28216-28225. 10.1074/jbc.M804174200, 2661392, 18701459.
191. Hirahara K, Yamashita M, Iwamura C, Shinoda K, Hasegawa A, Yoshizawa H, Koseki H, Gejyo F, Nakayama T. Repressor of GATA regulates TH2-driven allergic airway inflammation and airway hyperresponsiveness. J Allergy Clin Immunol 2008, 122:512-520. e511, 10.1016/j.jaci.2008.06.004, 18620745.
192. Kusam S, Toney LM, Sato H, Dent AL. Inhibition of Th2 differentiation and GATA-3 expression by BCL-6. J Immunol 2003, 170:2435-2441.
193. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007, 7:454-465. 10.1038/nri2093, 17525754.
194. Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, Komine O, Hamano S, Himeno K, Inagaki-Ohara K, et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med 2003, 9:1047-1054. 10.1038/nm896, 12847520.
195. Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, Esposito B, Perez N, Yasukawa H, Van Snick J, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009, 206:2067-2077. 10.1084/jem.20090545, 2757872, 19737863.
196. Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J, Naka T, Kishimoto T, Yoshimura A, Kubo M. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA 2002, 99:13003-13008. 10.1073/pnas.202477099, 130576, 12242343.
197. Ohshima M, Yokoyama A, Ohnishi H, Hamada H, Kohno N, Higaki J, Naka T. Overexpression of suppressor of cytokine signalling-5 augments eosinophilic airway inflammation in mice. Clin Exp Allergy 2007, 37:735-742. 10.1111/j.1365-2222.2007.02707.x, 17456221.
198. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol 2009, 182:4994-5002. 10.4049/jimmunol.0803560, 19342679.
199. Mattes J, Collison A, Plank M, Phipps S, Foster PS. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci USA 2009, 106:18704-18709. 10.1073/pnas.0905063106, 2773983, 19843690.
200. Hur GY, Lee SY, Lee SH, Kim SJ, Lee KJ, Jung JY, Lee EJ, Kang EH, Jung KH, Kim JH, et al. Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation. Exp Mol Med 2007, 39:367-375.
201. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima K, Ishimori M, Nagai H, Li YF, Yura T, Bacon KB. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003, 306:1174-1181. 10.1124/jpet.103.052316, 12766258.
202. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005, 115:791-796. 10.1016/j.jaci.2005.01.040, 15806000.
203. Kudlacz E, Conklyn M, Andresen C, Whitney-Pickett C, Changelian P. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 2008, 582:154-161. 10.1016/j.ejphar.2007.12.024, 18242596.
204. Malaviya R, Chen CL, Navara C, Liu XP, Keenan M, Waurzyniak B, Uckun FM. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther 2000, 295:912-926.
205. Malaviya R, Zhu D, Dibirdik I, Uckun FM. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem 1999, 274:27028-27038. 10.1074/jbc.274.38.27028, 10480916.
206. Duan W, Chan JH, Wong CH, Leung BP, Wong WS. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol 2004, 172:7053-7059.
207. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, Wong WS. Inhaled p38 alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 2005, 171:571-578.
208. Adcock IM, Chung KF, Caramori G, Ito K. Kinase inhibitors and airway inflammation. Eur J Pharmacol 2006, 533:118-132. 10.1016/j.ejphar.2005.12.054, 16469308.
209. Barnes PJ. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006, 109:238-245. 10.1016/j.pharmthera.2005.08.001, 16171872.
210. Gruenbaum LM, Schwartz R, Woska JR, DeLeon RP, Peet GW, Warren TC, Capolino A, Mara L, Morelock MM, Shrutkowski A, et al. Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. Biochem Pharmacol 2009, 77:422-432. 10.1016/j.bcp.2008.10.032, 19027720.
211. Chialda L, Zhang M, Brune K, Pahl A. Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. Respir Res 2005, 6:36. 10.1186/1465-9921-6-36, 1131927, 15833106.
212. Nath P, Eynott P, Leung SY, Adcock IM, Bennett BL, Chung KF. Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. Eur J Pharmacol 2005, 506:273-283. 10.1016/j.ejphar.2004.11.040, 15627438.
213. Trifilieff A, Keller TH, Press NJ, Howe T, Gedeck P, Beer D, Walker C. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol 2005, 144:1002-1010. 10.1038/sj.bjp.0706132, 1576082, 15685201.
214. Lee KS, Park SJ, Kim SR, Min KH, Lee KY, Choe YH, Hong SH, Lee YR, Kim JS, Hong SJ, Lee YC. Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. Eur Respir J 2008, 31:523-531. 10.1183/09031936.00125007, 18057050.
215. Park SJ, Min KH, Lee YC. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma. Respirology 2008, 13:764-771. 10.1111/j.1440-1843.2008.01369.x, 18811876.
216. Birrell MA, Hardaker E, Wong S, McCluskie K, Catley M, De Alba J, Newton R, Haj-Yahia S, Pun KT, Watts CJ, et al. Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. Am J Respir Crit Care Med 2005, 172:962-971. 10.1164/rccm.200412-1647OC, 16002568.
217. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, Sakai K, Inbe H, Takeshita K, Ishimori M, et al. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 2005, 145:178-192. 10.1038/sj.bjp.0706176, 1576128, 15753951.
218. Hirose K, Wakashin H, Oki M, Kagami S, Suto A, Ikeda K, Watanabe N, Iwamoto I, Furuichi Y, Nakajima H. GS143, an IkappaB ubiquitination inhibitor, inhibits allergic airway inflammation in mice. Biochem Biophys Res Commun 2008, 374:507-511. 10.1016/j.bbrc.2008.07.072, 18656449.
219. Lu S, Liu N, Dass SB, Reiss TF, Knorr BA. Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. Respir Med 2009, 103:342-347. 10.1016/j.rmed.2008.10.024, 19135348.
220. Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 2010, 11:26. 10.1186/1465-9921-11-26, 2841147, 20193079.
221. Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl) -3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]i soquinolin-4-one]. J Pharmacol Exp Ther 2006, 318:840-848. 10.1124/jpet.105.099192, 16682455.
222. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008, 226:19-28. 10.1111/j.1600-065X.2008.00697.x, 19161413.
223. Rothenberg ME, Owen WF, Silberstein DS, Woods J, Soberman RJ, Austen KF, Stevens RL. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. The Journal of clinical investigation 1988, 81:1986-1992. 10.1172/JCI113547, 442652, 3133397.
224. Valent P, Dahinden CA. Role of interleukins in the regulation of basophil development and secretion. Current opinion in hematology 2010, 17:60-66. 10.1097/MOH.0b013e328331fae9, 19741522.
225. Asquith KL, Ramshaw HS, Hansbro PM, Beagley KW, Lopez AF, Foster PS. The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J Immunol 2008, 180:1199-1206.
226. Webb DC, Cai Y, Matthaei KI, Foster PS. Comparative roles of IL-4, IL-13, and IL-4Ralpha in dendritic cell maturation and CD4+ Th2 cell function. J Immunol 2007, 178:219-227.
227. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. American journal of respiratory and critical care medicine 2010, 181:788-796. 10.1164/rccm.200909-1448OC, 20056900.
228. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-1431. 10.1016/S0140-6736(07)61600-6, 17950857.
229. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. European respiratory review: an official journal of the European Respiratory Society 2010, 19:46-54.
230. Leckie MJ. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2003, 2:245-259.
231. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148. 10.1016/S0140-6736(00)03496-6, 11191542.
232. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010, 125:1237-1244. e1232, 10.1016/j.jaci.2010.04.005, 20513521.
233. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. The New England journal of medicine 2009, 360:973-984. 10.1056/NEJMoa0808991, 19264686.
234. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360:985-993. 10.1056/NEJMoa0805435, 19264687.
235. Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997, 185:461-469. 10.1084/jem.185.3.461, 2196041, 9053446.
236. Mucida D, Salek-Ardakani S. Regulation of TH17 cells in the mucosal surfaces. J Allergy Clin Immunol 2009, 123:997-1003. 10.1016/j.jaci.2009.03.016, 2679861, 19362732.
237. Weissenbach M, Clahsen T, Weber C, Spitzer D, Wirth D, Vestweber D, Heinrich PC, Schaper F. Interleukin-6 is a direct mediator of T cell migration. Eur J Immunol 2004, 34:2895-2906. 10.1002/eji.200425237, 15368306.
238. Renauld JC, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J. Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J Immunol 1990, 144:4235-4241.
239. McLane MP, Haczku A, van de Rijn M, Weiss C, Ferrante V, MacDonald D, Renauld JC, Nicolaides NC, Holroyd KJ, Levitt RC. Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Am J Respir Cell Mol Biol 1998, 19:713-720.
240. Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998, 188:1307-1320. 10.1084/jem.188.7.1307, 2212487, 9763610.
241. White B, Leon F, White W, Robbie G. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther 2009, 31:728-740. 10.1016/j.clinthera.2009.04.019, 19446146.
242. Parker JM, Oh CK, Laforce C, Miller SD, Pearlman DS, Le C, Robbie GJ, White WI, White B, Molfino NA. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011, 11:14. 10.1186/1471-2466-11-14, 3058114, 21356110.
243. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008, 223:114-131. 10.1111/j.1600-065X.2008.00635.x, 18613832.
244. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 1998, 16:365-396. 10.3109/08830189809043002, 9505196.
245. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995, 182:1527-1536. 10.1084/jem.182.5.1527, 2192202, 7595222.
246. Bryan SA, O'Connor BJ, Matti S, Leckie MJ, Kanabar V, Khan J, Warrington SJ, Renzetti L, Rames A, Bock JA, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2149-2153. 10.1016/S0140-6736(00)03497-8, 11191543.
247. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103:779-788. 10.1172/JCI5909, 408149, 10079098.
248. Brightling CE, Saha S, Hollins F. Interleukin-13: prospects for new treatments. Clin Exp Allergy:journal of the British Society for Allergy and Clinical Immunology 2010, 40:42-49.
249. Kasaian MT, Miller DK. IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol 2008, 76:147-155. 10.1016/j.bcp.2008.04.002, 18502398.
250. Ishimitsu R, Nishimura H, Yajima T, Watase T, Kawauchi H, Yoshikai Y. Overexpression of IL-15 in vivo enhances Tc1 response, which inhibits allergic inflammation in a murine model of asthma. J Immunol 2001, 166:1991-2001.
251. Hellings PW, Kasran A, Liu Z, Vandekerckhove P, Wuyts A, Overbergh L, Mathieu C, Ceuppens JL. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003, 28:42-50. 10.1165/rcmb.4832, 12495931.
252. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, Fossiez F, Ryffel B, Schnyder B. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006, 203:2715-2725. 10.1084/jem.20061401, 2118159, 17101734.
253. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001, 19:423-474. 10.1146/annurev.immunol.19.1.423, 11244043.
254. Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 2001, 166:959-965.
255. Huang F, Wachi S, Thai P, Loukoianov A, Tan KH, Forteza RM, Wu R. Potentiation of IL-19 expression in airway epithelia by IL-17A and IL-4/IL-13: important implications in asthma. J Allergy Clin Immunol 2008, 121:1415-1421. 10.1016/j.jaci.2008.04.016, 18539194.
256. Liao SC, Cheng YC, Wang YC, Wang CW, Yang SM, Yu CK, Shieh CC, Cheng KC, Lee MF, Chiang SR, et al. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol 2004, 173:6712-6718.
257. Sivakumar PV, Foster DC, Clegg CH. Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. Immunology 2004, 112:177-182. 10.1111/j.1365-2567.2004.01886.x, 1782493, 15147560.
258. Besnard AG, Sabat R, Dumoutier L, Renauld JC, Willart M, Lambrecht B, Teixeira MM, Charron S, Fick L, Erard F, et al. Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med 2011, 183:1153-1163. 10.1164/rccm.201008-1383OC, 21297073.
259. Wakashin H, Hirose K, Maezawa Y, Kagami S, Suto A, Watanabe N, Saito Y, Hatano M, Tokuhisa T, Iwakura Y, et al. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med 2008, 178:1023-1032. 10.1164/rccm.200801-086OC, 18787221.
260. Li Y, Sun M, Cheng H, Li S, Liu L, Qiao H, Hua S, Lu J. Silencing IL-23 expression by a small hairpin RNA protects against asthma in mice. Exp Mol Med 2011, 43:197-204. 10.3858/emm.2011.43.4.024, 3085738, 21372631.
261. Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, Sturton G, Wong SH, McKenzie AN. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2007, 120:1324-1331. 10.1016/j.jaci.2007.07.051, 17889290.
262. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, Hippe A, Corrigan CJ, Dong C, Homey B, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med 2007, 204:1837-1847. 10.1084/jem.20070406, 2118667, 17635955.
263. Yoshimoto T, Yasuda K, Mizuguchi J, Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol 2007, 179:4415-4423.
264. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004, 5:752-760.
265. Lei Z, Liu G, Huang Q, Lv M, Zu R, Zhang GM, Feng ZH, Huang B. SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy 2008, 63:327-332.
266. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A, Kamradt T. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998, 95:6930-6935. 10.1073/pnas.95.12.6930, 22690, 9618516.
267. Xu D, Chan WL, Leung BP, Huang F, Wheeler R, Piedrafita D, Robinson JH, Liew FY. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998, 187:787-794. 10.1084/jem.187.5.787, 2212173, 9480988.
268. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490. 10.1016/j.immuni.2005.09.015, 16286016.
269. Shannon J, Ernst P, Yamauchi Y, Olivenstein R, Lemiere C, Foley S, Cicora L, Ludwig M, Hamid Q, Martin JG. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008, 133:420-426. 10.1378/chest.07-1881, 18071017.
270. Yang M, Kumar RK, Foster PS. Pathogenesis of steroid-resistant airway hyperresponsiveness: interaction between IFN-gamma and TLR4/MyD88 pathways. J Immunol 2009, 182:5107-5115. 10.4049/jimmunol.0803468, 19342691.
271. Boguniewicz M, Schneider LC, Milgrom H, Newell D, Kelly N, Tam P, Izu AE, Jaffe HS, Bucalo LR, Leung DY. Treatment of steroid-dependent asthma with recombinant interferon-gamma. Clin Exp Allergy 1993, 23:785-790. 10.1111/j.1365-2222.1993.tb00367.x, 10779310.
272. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 2000, 165:4773-4777.
273. Fattouh R, Midence NG, Arias K, Johnson JR, Walker TD, Goncharova S, Souza KP, Gregory RC, Lonning S, Gauldie J, Jordana M. Transforming growth factor-beta regulates house dust mite-induced allergic airway inflammation but not airway remodeling. Am J Respir Crit Care Med 2008, 177:593-603. 10.1164/rccm.200706-958OC, 18174546.
274. Alcorn JF, Rinaldi LM, Jaffe EF, van Loon M, Bates JH, Janssen-Heininger YM, Irvin CG. Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease. Am J Respir Crit Care Med 2007, 176:974-982. 10.1164/rccm.200702-334OC, 2078678, 17761617.
275. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008, 121:5-10. quiz 11-12, 10.1016/j.jaci.2007.10.028, 18036647.
276. Berry MA, Pavord ID. Antagonism of tumour necrosis factor alpha in refractory asthma. Thorax 2008, 63:571-572. 10.1136/thx.2007.095042, 18587028.
277. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558. 10.1164/rccm.200809-1512OC, 19136369.